LUT

Lutris Pharma is a private clinical-stage biopharmaceutical company based in Tel Aviv, Israel, focused on supportive oncology and improving adherence to anti-cancer therapy by reducing cutaneous toxicities. Its lead program, LUT014, is a proprietary topically applied B-Raf inhibitor gel being developed to treat epidermal growth factor receptor inhibitor-induced acneiform rash in patients receiving anti-EGFR cancer therapies. The company has also reported development activity for LUT-RD in radiation dermatitis. Lutris Pharma positions its products as enabling patients to stay on effective cancer regimens by mitigating dose-limiting dermatologic adverse events. The company raised a $30 million financing in January 2025 to advance LUT014 toward later-stage development and commercialization.